Skip to main content
Article
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma
Molecular Therapy (2016)
  • Anne M. Noonan, Ohio State University
  • Matthew R. Farren, Ohio State University
  • Susan M. Geyer, University of South Florida
  • Ying Huang, Ohio State University
  • Sanaa Tahiri, Ohio State University
  • Daniel Ahn, Ohio State University
  • Sameh Mikhail, Ohio State University
  • Kristen K. Ciombor, Ohio State University
  • Shubham Pant, University of Oklahoma
  • Santiago Aparo, Yeshiva University
  • Jennifer Sexton, Ohio State University
  • John L. Marshall, Georgetown University
  • Thomas A. Mace, Ohio State University
  • Christina S. Wu, Ohio State University
  • Bassel El-Rayes, Emory University
  • Cynthia D. Timmers, Ohio State University
  • James Zwiebel, National Institutes of Health
  • Gregory B. Lesinski, Ohio State University
  • Miguel A. Villalona-Calero, Ohio State University
  • Tanios S. Bekaii-Saab, Ohio State University
Publication Date
June 1, 2016
DOI
10.1038/mt.2016.66
Citation Information
Anne M. Noonan, Matthew R. Farren, Susan M. Geyer, Ying Huang, et al.. "Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma" Molecular Therapy Vol. 24 Iss. 6 (2016) p. 1150 - 1158
Available at: http://works.bepress.com/santiago-aparo/26/